New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:19 EDTCGIXCGI announces collaborative study results on kidney cancer microarray test
Cancer Genetics announced the results of a collaborative study conducted with The Cleveland Clinic to validate CGI's kidney cancer microarray test. The CGI kidney cancer microarray facilitates the diagnosis, sub-typing, and outcome prediction of kidney cancer patients. This study demonstrated that the diagnostic sensitivity of the test is 93%, with 99% specificity. The clinical validation study was performed using samples from 188 kidney cancer patients treated at the Cleveland Clinic. Accurately diagnosing kidney cancer using pathology alone is challenging, and can delay time to first treatment if surgical resections are required. Cancer Genetics is currently commercializing the test nationally by making it available as laboratory developed test. This study and final data were presented this week by Dr. Magi-Galluzzi of the Cleveland Clinic at a podium presentation at the 2014 United States & Canadian Academy of Pathology annual meeting in San Diego. These results provide additional evidence to support the clinical value of CGI's, unique, disease-focused, genomic tests.
News For CGIX From The Last 14 Days
Check below for free stories on CGIX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 21, 2014
07:47 EDTCGIXCancer Genetics to acquire Gentris
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use